CRIS Current Research Information System

CALZA, LEONARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.179
AS - Asia 11.626
EU - Europa 9.980
SA - Sud America 916
AF - Africa 653
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 36.374
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.010
CN - Cina 3.315
SG - Singapore 3.091
GB - Regno Unito 2.837
VN - Vietnam 2.706
DE - Germania 1.352
IT - Italia 1.258
UA - Ucraina 1.079
SE - Svezia 979
HK - Hong Kong 808
FR - Francia 774
BR - Brasile 684
IN - India 641
RU - Federazione Russa 616
IE - Irlanda 337
JP - Giappone 290
ZA - Sudafrica 233
KR - Corea 179
EE - Estonia 175
NL - Olanda 168
BD - Bangladesh 156
FI - Finlandia 124
TG - Togo 120
SC - Seychelles 106
AR - Argentina 102
CI - Costa d'Avorio 93
CA - Canada 77
PH - Filippine 67
ID - Indonesia 59
BG - Bulgaria 55
MX - Messico 53
TH - Thailandia 50
JO - Giordania 45
AT - Austria 40
CH - Svizzera 38
EC - Ecuador 34
IQ - Iraq 34
NG - Nigeria 26
PL - Polonia 26
CO - Colombia 25
TW - Taiwan 25
GR - Grecia 24
CL - Cile 23
TR - Turchia 23
BE - Belgio 21
UZ - Uzbekistan 21
ES - Italia 20
LB - Libano 20
PK - Pakistan 20
PY - Paraguay 17
VE - Venezuela 16
SA - Arabia Saudita 15
AU - Australia 12
EG - Egitto 11
KE - Kenya 11
PE - Perù 11
ET - Etiopia 10
IR - Iran 10
MA - Marocco 10
MY - Malesia 10
PT - Portogallo 10
RO - Romania 10
LT - Lituania 9
TN - Tunisia 8
NP - Nepal 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
JM - Giamaica 5
PA - Panama 5
AO - Angola 4
DO - Repubblica Dominicana 4
EU - Europa 4
GT - Guatemala 4
IL - Israele 4
BO - Bolivia 3
CR - Costa Rica 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
NI - Nicaragua 3
PS - Palestinian Territory 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AZ - Azerbaigian 2
BS - Bahamas 2
BY - Bielorussia 2
BZ - Belize 2
CV - Capo Verde 2
CY - Cipro 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
PR - Porto Rico 2
RS - Serbia 2
TL - Timor Orientale 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
Totale 36.343
Salva come PNG Salva come JPEG
Città #
Southend 2.518
Singapore 2.022
Ashburn 1.252
Fairfield 1.168
Jacksonville 772
Hong Kong 770
Chandler 707
San Jose 647
Santa Clara 624
Wilmington 615
Hefei 592
Woodbridge 579
Ho Chi Minh City 571
Princeton 556
Seattle 509
Hanoi 489
Houston 470
Dong Ket 417
Cambridge 395
Beijing 340
Dublin 337
Ann Arbor 331
Lauterbourg 327
Boardman 324
Council Bluffs 287
Nanjing 275
Bologna 264
Tokyo 258
Westminster 255
Padova 242
Los Angeles 204
Berlin 201
Seoul 151
Saint Petersburg 130
Buffalo 128
Mülheim 126
Jinan 125
Lomé 120
Milan 119
Shenyang 114
The Dalles 109
New York 105
Helsinki 98
San Diego 94
Abidjan 93
Medford 91
Dallas 90
Mahé 90
Nanchang 87
Hebei 81
Changsha 79
Redondo Beach 76
São Paulo 72
Tianjin 66
Guangzhou 64
Haiphong 64
Frankfurt am Main 57
Florence 55
Zhengzhou 55
Da Nang 54
Dearborn 54
Sofia 53
Verona 53
Hangzhou 50
Jiaxing 50
Chicago 47
Shanghai 47
Phoenix 46
Amman 45
Norwalk 42
Des Moines 41
Nuremberg 41
Bengaluru 40
Falls Church 40
Olalla 40
Turin 40
Ningbo 37
Yubileyny 37
Redmond 36
Kunming 34
Rome 32
San Francisco 32
Lanzhou 31
London 29
Hải Dương 27
Orem 27
Rio de Janeiro 27
Haikou 26
Abeokuta 24
Biên Hòa 24
Munich 24
Wuhan 24
Bangkok 23
Bühl 23
Can Tho 22
Quận Bình Thạnh 22
Xi'an 21
Shenzhen 20
Taizhou 20
Brooklyn 19
Totale 23.281
Salva come PNG Salva come JPEG
Nome #
Restriction Factors expression decreases in HIV-1 patients after cART 276
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 243
Acute onset myopericarditis as unusual presentation of primary HIV infection 238
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 238
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 234
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 221
A 2-year survey of bacteriologic profile and antimicrobial susceptibility levels of Enterococci in a large Italian teaching hospital. 216
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 213
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. 212
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 205
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 202
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 198
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 196
Abacavir-induced febrile agranulocytosis and anaemia. 193
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 193
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 191
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. 188
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 187
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 185
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 185
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 184
Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies 182
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 182
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 182
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 182
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 182
Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. 181
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 179
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 177
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 177
Pancreotoxicity of propofol sedation during purulent meningitis. 175
Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological, and imaging response of lung tuberculosis to specific treatment. Which role for linezolid? 175
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 173
Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy 173
HIV and kidney: A dangerous liaison 172
Measles outbreak in the city of Bologna, December 2007 to May 2008 171
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 171
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. 171
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 171
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 170
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 170
Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. 169
Molecular Bases of Osteoporosis in HIV: The Role of the Virus and Antiretroviral Therapy 169
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 169
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 169
A prospective comparison of hepatotoxicity of the two currently available non-nucleoside reverse transcriptase inhibitors in a homogeneous case-mix of HIV-infected patients treated for the first time with efavirenz or nevirapine, according to their different baseline conditions 167
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 167
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 167
Bone mass loss in patients with human immunodeficiency virus type 1 infection: association with male sex and protease inhibitor therapy 165
Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy 165
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir 165
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 165
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 164
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. 163
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 162
Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine 162
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 162
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. 161
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. 160
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. 160
Methicillin-resistant staphylococci still susceptible to non-beta-lactam antibiotics. What clinical implications in nosocomially-acquired infections? 159
Legionnaires' disease associated with macular rash: two cases 158
Severe peripheral neuropathy with areflexic and flaccid quadriplegia complicating Legionnaires’ disease in an adult patient. 158
Polyunsaturated ethyl esters on n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. 157
Loss of bone mass in chronically HIV-infected patients. Significant association with male gender and protease inhibitor administration 157
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection. 157
First-line efavirenz versus lopinavir/ritonavir-based highly active antiretroviral therapy for naïve patients. 156
An observational study of subcutaneous multiple lipomatosis in patients receiving highly active antiretroviral therapy. Possible correlations with metabolic abnormalities and pathogenetic insights 155
Primary Cytomegalovirus infection in otherwise healthy adults with Fever of Unknown Origin: a 3-year prospective survey 154
Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. 153
Aderenza alla terapia antiretrovirale "autogestita" dai pazienti alla metà della posologia giornaliera raccomandata. Inattesa efficacia immunologica e virologica a lungo termine 153
Antiretroviral therapy voluntarily taken at half-dosage, but fully effective after 6-10 years: a provocative issue for adherence requirements. Case report 153
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. 153
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 151
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy 151
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. 149
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy? 148
Antiretroviral treatment and gynecomastia: which correlations? 147
Changing epidemiology of hepatitis A in the Bologna metropolitan area, northern Italy: importance of counselling and prophylactic measures for the male homo/bisexual population. 147
Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study. 147
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 147
Comparison between switching therapy from protease inhibitors to an NNRTI and lipid-lowering therapy with pravastatin or bezafibratef for the management of HAART-related dyslipidemia 146
Diffuse skin spread of HIV-associated visceral leishmaniasis: cumbersome diagnostic and therapeutic issues 146
Cardiovascular prevention in HIV-positive individuals on antiretroviral therapy.. The paradigm shift has already happened: Is it time to wake up and realise it? 146
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 146
Safety issues about nevirapine administration in HIV-infected pregnant women 145
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 145
Bladder carcinoma and HIV infection during the highly active antiretroviral therapy era: a rare, but intriguing association. Two case reports and literature review 145
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration 143
An extremely different dysmetabolic profile between the two available nonucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. 142
Severe brain co-infection with Cryptococcus neoformans and Mycobacterium tuberculosis in a young, otherwise healthy student recently immigrated from China 142
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up 142
Metabolic alterations in human immunodeficiency virus-infected patients treated with antiretroviral therapy 141
HIV infection and the pancreas: risk factors and potential management guidelines 141
Stabilizzazione a lungo termine dell'assetto virologico e immunologico dell'infezione da HIV in un "AIDS Presenter" seguito per oltre vent'anni, nonostante la mancata aderenza alla terapia antiretrovirale 141
Chron’s disease, rare association with selective IgA immunodeficiency, and development of life-threatening bacterial infections. 141
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 141
Novel understanding on genetic mechanisms of enteric neuropathies leading to severe gut dysmotility 141
Sensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to antimicrobial agents other than beta-lactams: profile and trend, 1998-2003 140
First-line efavirenz- versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients 140
Totale 16.969
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.299
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.299
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021853 0 0 0 0 0 0 0 0 0 0 0 853
2021/20224.312 402 215 284 406 405 262 77 331 146 349 732 703
2022/20233.746 467 596 209 473 237 225 127 188 621 118 361 124
2023/2024867 72 156 63 98 66 158 51 62 25 64 23 29
2024/20254.519 118 901 407 359 976 204 251 89 38 202 81 893
2025/202611.493 709 1.187 1.261 1.003 1.264 661 979 499 2.077 984 423 446
Totale 36.958